Levine Cancer Institute, Atrium Health, 1021 Morehead Medical Drive, Suite 1000, Charlotte, NC, 28204, USA.
Southeast Radiation Oncology Group, Charlotte, NC, USA.
Radiat Oncol. 2021 Feb 4;16(1):28. doi: 10.1186/s13014-021-01760-2.
Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus is a current pandemic. We initiated a program of systematic SARS-CoV-2 polymerase chain reaction (PCR) testing in all asymptomatic patients receiving radiotherapy (RT) at a large radiation oncology network in the Charlotte, NC metropolitan region and report adherence and results of the testing program.
Patients undergoing simulation for RT between May 18, 2020 and July 10, 2020 within the Levine Cancer Institute radiation oncology network who were asymptomatic for COVID-19 associated symptoms, without previous positive SARS-CoV-2 testing, and without recent high-risk contacts were included. PCR testing was performed on nasal cavity or nasopharyngeal swab samples. Testing was performed within 2 weeks of RT start (pre-RT) and at least every 4 weeks during RT for patients with prolonged RT courses (intra-RT). An automated task based process using the oncology electronic medical record (EMR) was developed specifically for this purpose.
A total of 604 unique patients were included in the cohort. Details on testing workflow and implementation are described herein. Pre-RT PCR testing was performed in 573 (94.9%) patients, of which 4 (0.7%) were positive. The adherence rate to intra-RT testing overall was 91.6%. Four additional patients (0.7%) tested positive during their RT course, of whom 3 were tested due to symptom development and 1 was asymptomatic and identified via systematic testing. A total of 8 (1.3%) patients tested positive overall. There were no known cases of SARS-CoV-2 transmission from infected patients to clinic staff and/or other patients.
We detailed the workflows used to implement systematic SARS-CoV-2 for asymptomatic patients at a large radiation oncology network. Adherence rates for pre-RT and intra-RT testing were high using this process. This information allowed for appropriate delay in initiating RT, minimizing the occurrence of RT treatment interruptions, and no known cases of transmission from infected patients to clinic staff and/or other patients.
由 SARS-CoV-2 病毒引起的 2019 年冠状病毒病(COVID-19)是当前的大流行疾病。我们在北卡罗来纳州夏洛特市大都会区的一个大型肿瘤放射治疗网络中,对所有接受放射治疗(RT)的无症状患者启动了一项系统的 SARS-CoV-2 聚合酶链反应(PCR)检测计划,并报告了该检测计划的依从性和结果。
纳入 2020 年 5 月 18 日至 2020 年 7 月 10 日期间在莱文癌症研究所肿瘤放射治疗网络中接受 RT 模拟的无症状 COVID-19 相关症状、无既往 SARS-CoV-2 检测阳性且无近期高危接触的患者。对鼻腔或鼻咽拭子样本进行 PCR 检测。对于 RT 疗程较长的患者(RT 期间),在 RT 开始后 2 周内(RT 前)和 RT 期间至少每 4 周进行一次检测。专门为此目的开发了一个基于肿瘤学电子病历(EMR)的自动化任务流程。
共纳入 604 例患者。本文详细描述了检测工作流程和实施情况。573 例(94.9%)患者进行了 RT 前 PCR 检测,其中 4 例(0.7%)呈阳性。总体而言,RT 期间检测的依从率为 91.6%。4 例患者(0.7%)在 RT 期间检测呈阳性,其中 3 例因症状出现而检测,1 例无症状,通过系统检测发现。共有 8 例(1.3%)患者总检测呈阳性。无已知的 SARS-CoV-2 从感染患者传播给临床工作人员和/或其他患者的病例。
我们详细介绍了在大型肿瘤放射治疗网络中对无症状患者实施系统 SARS-CoV-2 检测的工作流程。通过该流程,RT 前和 RT 期间检测的依从率很高。这些信息使 RT 的启动适当延迟,最大限度地减少 RT 治疗中断的发生,且无已知的感染患者向临床工作人员和/或其他患者传播的病例。